CJC-1295 + Ipamorelin: The Complete Guide

Overview: The Most Studied GH-Axis Combination in Research

CJC-1295 and Ipamorelin are two of the most extensively researched growth hormone axis compounds available. While each has a distinct mechanism and research profile, they are most commonly studied in combination — a pairing that has become one of the most popular protocols in GH-axis research due to the complementary and potentially synergistic nature of their mechanisms.

Understanding each compound individually, and then understanding why researchers combine them, is essential context for anyone designing GH-axis research protocols.

CJC-1295: A GHRH Analogue

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that stimulates the pituitary gland to produce and release growth hormone. It consists of the first 29 amino acids of GHRH with several modifications designed to improve stability and extend half-life.

CJC-1295 is available in two distinct forms that are important to distinguish in research design:

• CJC-1295 without DAC (also called Mod GRF 1-29) — the shorter-acting form with a half-life of approximately 30 minutes. This form produces a more physiological, pulsatile GH release pattern when dosed multiple times daily.
• CJC-1295 with DAC (Drug Affinity Complex) — incorporates a lysine-maleimidoproprionic acid modification that enables covalent binding to serum albumin, extending the half-life to approximately 6-8 days. This produces sustained, non-pulsatile GH elevation.

The choice between DAC and non-DAC forms is a meaningful research design decision — pulsatile versus continuous GH secretion produces different downstream effects on IGF-1 levels, tissue responses, and metabolic outcomes.

CJC-1295 Mechanism

CJC-1295 binds to the GHRH receptor (GHRHR) on pituitary somatotrophs, activating the Gs-cAMP-PKA signaling pathway that drives GH synthesis and secretion. Like all GHRH analogues, it operates within the physiological GH regulatory axis — remaining subject to somatostatin inhibition and IGF-1 negative feedback. This preserved feedback regulation is a key methodological advantage over exogenous GH administration in research protocols where axis integrity is a variable of interest.

Ipamorelin: A Selective GHRP

What Is Ipamorelin?

Ipamorelin is a synthetic growth hormone-releasing peptide (GHRP) — a pentapeptide that acts as a selective agonist at the ghrelin receptor (also known as the growth hormone secretagogue receptor, GHS-R). It was developed as a research compound specifically for its selectivity: unlike earlier GHRPs such as GHRP-2 and GHRP-6, ipamorelin stimulates GH release with minimal effects on cortisol, prolactin, or ACTH secretion.

With a molecular weight of 711.86 Da and a short plasma half-life of approximately 2 hours, ipamorelin is designed for studies requiring acute, controllable GH pulse induction rather than sustained GH elevation.

Ipamorelin Mechanism

Ipamorelin binds to the GHS-R1a receptor in the pituitary and hypothalamus, activating a Gq/11-protein coupled signaling cascade that stimulates GH secretion through pathways distinct from — but complementary to — the GHRH receptor pathway. GHS-R activation also suppresses somatostatin release from the hypothalamus, reducing the inhibitory brake on GH secretion.

The ghrelin receptor pathway and the GHRH receptor pathway are distinct and can be simultaneously activated, which is the mechanistic basis for the synergistic GH release observed when GHRPs and GHRH analogues are co-administered.

Why Researchers Combine CJC-1295 and Ipamorelin

Dual Pathway Activation

The combination of a GHRH analogue (CJC-1295) with a GHRP (Ipamorelin) simultaneously activates two distinct receptor pathways that converge on GH secretion. The GHRH receptor pathway and the ghrelin receptor pathway are additive — and in some research models, synergistic — in stimulating GH release from pituitary somatotrophs.

Studies have demonstrated that co-administration of a GHRH analogue and a GHRP produces significantly greater GH release than either compound alone at equivalent doses. This synergistic effect has been attributed to the complementary intracellular signaling cascades (cAMP via GHRHR vs. Gq/11 via GHS-R) that potentiate each other’s effects on GH secretion.

Physiological Pulse Amplification

The combination is designed to amplify the natural pulsatile pattern of GH secretion rather than replace it with continuous elevation. When CJC-1295 (without DAC) and Ipamorelin are co-administered, they work together to produce robust GH pulses that mimic — at higher amplitude — the natural pulsatile GH secretion that occurs during deep sleep and fasting states. This pulse amplification approach is methodologically important for research where GH pulse dynamics, rather than sustained GH levels, are the primary variable.

Research Applications of the Combination

GH Axis Research

The CJC-1295/Ipamorelin combination is the standard research protocol for investigators studying the growth hormone axis, GH secretion dynamics, IGF-1 regulation, and downstream somatotropic signaling. The combination allows researchers to produce reliable, reproducible GH pulses at controlled intervals.

Body Composition Research

GH plays well-established roles in lipolysis, protein synthesis, and body composition regulation. Research using CJC-1295/Ipamorelin has investigated effects on fat mass, lean mass, bone density, and metabolic rate in relevant animal models — examining whether GH pulse amplification through dual pathway activation produces measurable body composition changes distinct from those seen with individual compounds.

Sleep and Recovery Research

GH secretion is highest during slow-wave sleep, and the GH axis plays roles in tissue repair, protein synthesis, and cellular recovery processes. Research has investigated the CJC-1295/Ipamorelin combination in sleep physiology and recovery models, examining GH pulse patterns during sleep, the relationship between GH secretion and slow-wave sleep architecture, and downstream recovery markers.

Age-Related Somatotropic Decline

GH secretion declines substantially with age (somatopause). The CJC-1295/Ipamorelin combination has been used in aging research models to investigate whether dual-pathway GH axis stimulation can restore more youthful GH secretion patterns and whether this restoration affects age-related changes in body composition, bone density, cognitive function, and metabolic markers.

Distinguishing Research Protocols: DAC vs Non-DAC

The choice of CJC-1295 form significantly impacts research design:

• CJC-1295 without DAC + Ipamorelin — produces discrete, controlled GH pulses. Appropriate for research investigating acute GH dynamics, pulsatile secretion patterns, and GH pulse-dependent downstream effects.
• CJC-1295 with DAC + Ipamorelin — produces sustained background GH elevation combined with Ipamorelin-induced pulses. Appropriate for research investigating sustained GH elevation effects on body composition, IGF-1 levels, and tissue anabolism.

Formulation and Storage

Both compounds are available as lyophilized powders. CJC-1295 without DAC has a molecular weight of 3,367.97 Da; CJC-1295 with DAC is approximately 3,647.28 Da. Ipamorelin has a molecular weight of 711.86 Da. Both should be reconstituted in bacteriostatic water and stored at 2–8°C after reconstitution. Lyophilized forms are stable at -20°C.

Research-grade purity for both compounds should be verified at ≥99% by HPLC. Researchers combining the two compounds should verify COAs for each independently.

Shop Ipamorelin at AminoForge Shop CJC-1295 No DAC at AminoForge or CJC-1295 DAC at AminoForge

Ipamorelin selective GH secretagogue research

All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.